ASMI S3 ad reform push

November 23, 2015

THe Australian Self-Medication Industry has vowed to continue its advocacy for Schedule 3 advertising reforms, in the face of recommendations that restrictions be retained in the State Two Expert Panel report on the regulatory framework for medicines and medical devices (PD Fri). Despite suggesting some revisions, to provide for a formal risk-benefit methodology for S3 items to be included in Appendix H, the panel didn’t recommend removing all S3 ad restrictions. However ASMI chief executive officer Deon Schoombie said the organisation supports the majority of the report, saying “we are pleased the Panel recommended a risk-based approach to regulation and accepted many of the proposals industry put forward”. Schoombie said ASMI reserves judgement about the Panel’s recommendations on complaints handling and pre-vetting of advertisements “as these two areas are highly complex, involve several inter-connected systems and will require a suite of additional reforms”.

The above article was sent to subscribers in Pharmacy Daily's issue from 23 Nov 15
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Nov 15

Other recent headlines

Legal action for Montu
Friday | Apr 19 2024

MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.

Call to unblock wait times
Friday | Apr 19 2024

AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).

New pelvic pain study
Friday | Apr 19 2024

THE University of South Australia has released a new study to help healthcare workers better support women with persistent pelvic pain, including symptoms that are suggestive of gynaecological, lower urinary tract, bowel, sexual, and pelvic floor dysfunction.

SEARCH PHARMACY DAILY

Featured video
MORE VIDEOS

Recent issues

PD for Fri 19 Apr 2024
PD for Thu 18 Apr 2024
PD for Wed 17 Apr 2024
PD for Tue 16 Apr 2024
PD for Mon 15 Apr 2024
SEE MORE ISSUES

INDUSTRY JOB VACANCIES

Pharmacist in Charge – SA
Pharmacist Manager – WA
Compounding Pharmacist – Melbourne
Pharmacist in Charge – QLD North
Pharmacist – Sydney North
SEE MORE JOBS

Pharmacy Daily is Australia's favourite online publication dedicated to the pharmacy industry. The publication launched in March 2007 and is distributed every day by email to pharmacists across the country.

PHARMACY DAILY NEWS
Headlines

Jobs

New Products

Events Calendar

FEEDS
News Items RSS feed

PD Issues RSS feed

All content RSS feed

Content & Media
Pharmacy Daily TV

OUR SITES
Sitemap

Travel Daily

Travel Bulletin

Cruise Weekly

Business Events News

Pharmacy Daily

ADVERTISE WITH US
Advertise in Pharmacy Daily

Privacy

ADMIN
Log in

SUBSCRIBE
Sign up for FREE

Subscription Information

"Water, air, and cleanness are the chief articles in my pharmacy." - Napoleon Bonaparte

Copyright © 2018 Pharmacy Daily

Subscribe to Pharmacy Daily now!

FREE Pharmacy Daily subscription - never miss another story!

Name*
First Last
Email*

Profession
Company

Address
City State / Province / Region ZIP / Postal Code Country

By submitting this form I hereby certify that I understand that Pharmacy Daily is a publication for health professionals.
Comments
This field is for validation purposes and should be left unchanged.

to top

Pharmacy Daily | ASMI S3 ad reform push

ASMI S3 ad reform push

Other recent headlines

Legal action for Montu

Call to unblock wait times

New pelvic pain study

SEARCH PHARMACY DAILY

Featured video

Recent issues

INDUSTRY JOB VACANCIES